News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fournier Pharma Has Been Granted Orphan Drug Designation By The European Commission (EC) For ANATIBANT For The Treatment Of Moderate And Severe Traumatic Brain Injury


10/19/2005 5:10:39 PM

Fournier Pharma announced today that ANATIBANT has been granted orphan drug designation by the European Commission (EC) for the treatment of moderate and severe traumatic brain injury following the favorable opinion of the European Agency for the Evaluation of Medicinal Products (EMEA).



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES